Abstract. Pulse wave velocity (PWV) is known to represent arterial stiffness and is established as a marker for cardiovascular risk and a prognostic factor for mortality in the case of chronic renal failure or hypertension. The application of an automated apparatus for measuring brachial-ankle pulse wave velocity (baPWV) has made PWV measurement non-invasive, easier to screen for cardiovascular risk and as a result, baPWV measurements have become widely applied in clinical practice in recent years. We assessed the baPWV in 7 flank hypothyroidism patients and 28 subclinical hypothyroidism patients. In comparison with age matched healthy controls, 3 hypothyroid patients had advanced values and by replacement therapy, all 7 subjects showed improvement in their baPWV values (1531.2 ± 242.7 to 1330.2 ± 208.6 cm/s, p<0.05). In 28 subclinical hypothyroid subjects, 71% also had accelerated baPWV values for their age. Ten subjects (36% of all) had neither hypertension, hyperlipidemia, diabetes nor were taking any medication, and yet 8 patients out of 10 showed advanced baPWV values compared to age matched mean values. The baPWV was not correlated to TSH or total cholesterol levels, and was associated with only age and blood pressure (p = 0.01, <0.001, respectively), which are widely demonstrated as the characteristics for baPWV. In two subclinical hypothyroid subjects, who were normotensive and had no dyslipidemia, thyroxine treatment was performed and the baPWV decreased with unchanged blood pressure and total cholesterol levels. We concluded that the arterial wall stiffness tends to be increased in both overt and subclinical hypothyroid patients, and an appropriate treatment could reverse the abnormalities. It is possible that the initiation of adequate treatment in subclinical hypothyroidism may reduce the cardiovascular risk.
THE cardiovascular system is very sensitive to thyroid function. Symptoms of hypothyroidism are mostly cardiac manifestations. The presence of hypertension and hypercholesterolemia contributes to atherogenesis, and overt hypothyroidism is widely recognized as a risk factor for cardiovascular disease. Thyroxine replacement therapy reverses all the cardiac abnormalities; however, in elderly patients with suspected ischemic heart disease, a smaller dose should be given initially and the dose should be increased in a stepwise fashion up to the anticipated dose [1, 2] .
From another aspect, subclinical hypothyroidism, the prevalence of which seems to be much higher than overt hypothyroidism [3] , has also been observed to be associated with the derangement of cardiac function and is a strong indicator of the risk of atherosclerosis and myocardial infarction in elderly women [4] and men [5] . If subclinical hypothyroid subjects have an increased risk of ischemic heart disease, timely treatment should be considered and the treatment should offer benefit with minimal risk [6] .
For the above reasons, it is important to assess the cardiovascular risk associated with overt and subclinical hypothyroidism prior to replacement therapy. However, a biochemical evaluation, such as the lipid profile alone, is not fully predictive of early atherosclerotic changes and from the oppositing aspect, the per-formance of invasive coronary angiography on all these subjects would not be approved in general practice.
Intima-media-thickness (IMT) is considered to be an early indicator of atherosclerosis. In a recent report by Monzani et al., subclinical hypothyroidism was shown to be associated with early stage carotid atherosclerosis by ultrasonography and replacement therapy of thyroxine was able to improve atherogenic lipoprotein profile and intima-media thickening [7] .
Pulse wave velocity (PWV) is also a direct parameter of arterial stiffness and an association with mortality and cardiovascular lesions has been demonstrated [8, 9] . In a previous study, increased central arterial stiffness and reversal by thyroxine treatment in overt hypothyroidism was demonstrated [10] . Their measurement was based on tonometry applied to the radial artery and from this the central arterial stiffness was mathematically transformed. In the present study, automated brachial ankle pulse wave velocity (baPWV) measurements using the oscillometric method were utilized and its inter-and intra-assay variability was shown to be small [11] . We performed baPWV measurements in both overt and subclinical hypothyroid patients and investigated whether these patients have an increased risk of ischemic heart disease and also tested whether thyroid hormone replacement therapy affects the baPWV measurement.
Subjects and Methods

1) Biochemical measurements
Serum concentration of TSH, free T4 (FT4) and free T3 (FT3) and other biochemical markers were measured in 7 overt hypothyroidism and 28 subclinical hypothyroid subjects.
2) BaPWV measurement
The baPW measurement was performed with plethysmography (Form PWV/ABI from Colin Medical Technology, Tokyo, Japan) at the time of the initial check up and after replacement therapy in the subjects treated by thyroxine. Using Form PWV/ABI, cardiac indexes such as PEP (preejection period), ET (ejection time) were also examined [12] , both of which are known to be affected by the thyroid hormone status and the ABI (ankle brachial index) was simultaneously recorded. Subjects were examined in the supine position after a sufficient period of resting time. Age and sex matched mean values were estimated by data taken from healthy subjects [13] .
3) Statistical Analysis
StatView version 5 (Abacus Concepts, Inc., Berkeley, CA) was used to perform all of the statistical calculations. The significance of changes before and after treatment values was estimated by the paired t-test; p values below 0.05 were considered to be significant.
Results
1) Overt hypothyroidism
Seven patients' characteristics are shown in Table 1 . All of them had primary hypothyroidism, as evidenced by their elevated TSH. Two of the subjects had hypercholesterolemia, and one had hypertension. None of the seven were on medication at baseline. Three subjects showed increased baPWV values compared to age and sex matched control values. At the baseline, the baPWV did not correlate with TSH, f-T4,f-T3 or cholesterol levels. After replacement therapy after a median interval of 67 days, the FT4 increased from 0.48 ± 0.08 to 0.97 ± 0.09 pg/ml, p<0.05). The baPWV values decreased from 1531.2 ± 242.7 to 1330.2 ± 208.6 cm/s, p<0.05 (Fig. 1) . While blood pressure is an important determinant of baPWV, the blood pressure was not altered significantly between the two measurements. The mean PEP significantly decreased (p<0.05); however, in the present study, the heart rate and ET or ABI were not affected (Table 1) .
There was no correlation between the differences in baPWV and thyroid hormone increment or cholesterol change (data not shown). To exclude the interference by age or other factors that might have affected the baPWV, we selected two young females who would generally lack atherosclerotic risk factors. Interestingly, their baPWV values, which were appropriate for their age at the initial measurement, improved after treatment ( Table 2 , Fig. 2 ).
2) Subclinical hypothyroidism
Twenty-eight (11 male, 17 female) subjects were evaluated and their characteristics and hormonal profiles are shown in Table 3 . Eight subjects were on medications for hypertension (n = 1), hyperlipidemia (n = 2) or both (n = 2) and diabetes (n = 3). The mean age was 58.9 ± 1.7 years and the TSH was 6.43 ± 0.6 mU/L (mean ± SEM). There was only an association between the baPWV and the age or blood pressure, as reported previously [14] . There was no correlation between the TSH and cholesterol levels (data not shown).
No correlations were found between TSH, thyroid hormone levels or cholesterol and baPWV (Fig. 3) . Twenty subjects (71%) showed advanced age values, estimated by baPWV (Fig. 4 ). An association with either hypertension or hypercholesterolemia might have affected the above estimation; however, in the subjects who showed advanced baPWV levels for their age, 58% were normotensive, and 76% had normal lipid profiles. Moreover, ten subjects (36% of all) had neither hypertension, hyperlipidemia, diabetes nor were they taking any medication, and yet 8 patients out of 10 showed advanced baPWV values compared to age matched mean values. In these 28 subjects, 16 had a TSH value below 10 mU/L, to whom replacement therapy would not be indicated in general practice. In two patients, in whom TSH exceeded 10 mU/L, thyroxine was given under informed consent. (Fig. 5) . In both subjects, serum cholesterol levels were normal at baseline (total cholesterol 173, 178 mg/dl, respectively), and were not altered after thyroxine replacement (178, 174 mg/dl), and significant blood pressure changes were not observed (102/65 to 104/65, 136/98 to 137/87, respectively). 
Discussion
The relationship between hypothyroidism and atherosclerosis is evident according to a body of clinical reports, epidemiological studies and biochemical observations. In a hospital based-study, men and women with a TSH level of 4.0 mIU/ml or greater had higher prevalence of coronary artery disease than age matched controls (48% vs. 38% for men and 37% vs. 20% for women), although this was significant only for women [4] . Overt hypothyroidism is associated with increased risk factors for cardiovascular disease indicated by elevated levels of total cholesterol, LDL-cholesterol and apolipoprotein B. Hypothyroidism also causes diastolic hypertension that is possibly due to increased peripheral vascular resistance. Vasoconstriction may reflect the absence of vasodilatory T3 effects on vascular smooth muscle.
The relationship between subclinical hypothyroidism and atherogenesis is also shown in the same context as overt hypothyroidism, although some controversy remains with respect to the causal relationship and necessity of treatment [15, 16] . In the Whickham Survey, an English cohort study of 2779 men and women, among 132 subjects followed for 20 years there was no relationship between autoimmune thyroid disease and incidents of ischemic heart disease and mortality [17] . In contrast, the most compelling data suggesting a greater cardiovascular risk in patients with subclinical hypothyroidism came from the Rotterdam Study [4] . In a cross-sectional analysis of 1149 women aged 55 yr or over, women with subclinical hypothyroidism had a higher prevalence of atherosclerosis on chest X-ray (odds ratio, 1.9) and a higher prevalence of myocardial infarction (odds ratio, 2.3) than euthyroid women after adjustment for age, body mass index, HDL-C, blood pressure and smoking status. Recently, a report from Japan showed that subclinical hypothyroidism is associated with an increased risk for ischemic heart disease or mortality in men with an odds ratio of 2.5 adjusted for age, blood pressure, body mass index, cholesterol, smoking, erythrocyte sedimentation rate, or the presence of diabetes [5] .
For the above reasons, to accurately evaluate the risk factors in hypothyroid subjects is important. In overt hypothyroidism, measures of arterial stiffness were performed by a tonometric method and it was shown that hypothyroidism was associated with increased central arterial stiffness and the abnormalities were reversed after adequate thyroxine replacement [10] . IMT is also established as an early marker of systemic atherosclerosis and coronary heart disease. In both overt and subclinical hypothyroid subjects, increased IMT was shown [7, 18] indicating early atherogenic process in subclinical hypothyroid status. Our data confirmed the above reports by utilizing a separate method, namely baPWV. Measurement of baPWV is standardized, and a validated approach for the screening of atherosclerotic risk [19] [20] [21] . Subjects with hypothyroidism have a tendency to have increased baPWV compared to age-matched healthy controls, and the changes are reversed by appropriate thyroxine replacement, although the numbers treated in the present study were small. Appropriate treatment with thyroxine is able to reverse baPWV to a considerable degree, which may be beneficial in reducing coronary heart disease. These changes are not ascribed to assay variance or blood pressure changes, since the reproducibility of baPWV measurements was shown to be correct and blood pressures were not changed in the present study.
Subclinical hypothyroidism has been detected with increasing frequency in recent years; however, the issue of treatment when serum TSH is slightly elevated is still under debate. Previous reports [7, 10] and the present study have shown that the early atherogenic process is present even in subclinical hypothyroidism. The association between dyslipidemia and subclinical hypothyroidism is well documented, and treatment by thyroxine is shown to reverse the abnormality [22] . In our patients, no relationships between baPWV and thyroid hormone levels or serum cholesterol were observed. On the other hand, there is a report that elevated TSH levels are associated with LDL-C, the total cholesterol in the insulin resistant state [23] . However, we could not demonstrate an association between TSH and cholesterol. It is likely that the observed improvement in both overt and subclinical hypothyroidism was due to a direct effect of the thyroid hormone [24] . It is shown that mild hypothyroid hormone deficiency per se is responsible for impaired endothelial function [25, 26] and that impaired endothelial function may be reflected by increased arterial stiffness [27, 28] . It has been suggested that baPWV reversal by thyroxine replacement means that the increased baPWV may reflect components of reversible changes i.e. endothelial dysfunction, which in long term eventually induces the irreversible pathological process toward atherosclerosis.
Overall, combining the previous findings with our own, the early atherogenic process in both overt and subclincal hypothyroidism was suggested. Whether the baPWV increase is related to an early atherosclerotic involvement of the arterial wall can not be directly decided from our study, the fact that an appropriate treatment was able to reverse the changes suggests that there may be a mechanism which increases the arterial stiffness underlying the hypothyroid status. It would seem appropriate to initiate timely treatment when an increased atherogenic risk is indicated by either IMT or baPWV, in addition to considering the other classical risk factors, such as dyslipidemia, diabetes, hypertension and smoking.
